このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

VBI Vaccines 将来の成長

Future 基準チェック /26

VBI Vaccinesは、66.2%と48.9%でそれぞれ年率66.2%で利益と収益が成長すると予測される一方、EPSはgrowで72.8%年率。

主要情報

66.2%

収益成長率

72.8%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	48.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 May 2024

今後の成長に関する最新情報

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation

Oct 31

業績と収益の成長予測

NasdaqCM:VBIV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	59	-14	-11	-3	1
12/31/2025	34	-15	-8	-10	1
12/31/2024	13	-42	-37	-37	1
3/31/2024	9	-84	-51	-51	N/A
12/31/2023	9	-94	-62	-61	N/A
9/30/2023	8	-115	-70	-68	N/A
6/30/2023	2	-119	-81	-77	N/A
3/31/2023	1	-120	-80	-75	N/A
12/31/2022	1	-113	-78	-74	N/A
9/30/2022	1	-111	-77	-73	N/A
6/30/2022	1	-102	-63	-60	N/A
3/31/2022	0	-73	-55	-53	N/A
12/31/2021	1	-70	-42	-40	N/A
9/30/2021	1	-66	-40	-38	N/A
6/30/2021	1	-63	-51	-49	N/A
3/31/2021	1	-56	-47	-46	N/A
12/31/2020	1	-46	-48	-47	N/A
9/30/2020	1	-42	-40	-39	N/A
6/30/2020	2	-45	-39	-38	N/A
3/31/2020	2	-49	-44	-42	N/A
12/31/2019	2	-55	-52	-49	N/A
9/30/2019	4	-63	-54	-48	N/A
6/30/2019	4	-62	-54	-47	N/A
3/31/2019	4	-66	-58	-51	N/A
12/31/2018	3	-64	-52	-46	N/A
9/30/2018	1	-56	-51	-47	N/A
6/30/2018	1	-50	-42	-40	N/A
3/31/2018	1	-43	-33	-32	N/A
12/31/2017	1	-39	N/A	-31	N/A
9/30/2017	1	-36	N/A	-30	N/A
6/30/2017	1	-33	N/A	-28	N/A
3/31/2017	1	-31	N/A	-25	N/A
12/31/2016	1	-23	N/A	-19	N/A
9/30/2016	0	-19	N/A	-14	N/A
6/30/2016	0	-31	N/A	-14	N/A
3/31/2016	1	-25	N/A	-9	N/A
12/31/2015	1	-26	N/A	-9	N/A
9/30/2015	2	-23	N/A	-8	N/A
6/30/2015	2	-6	N/A	-7	N/A
3/31/2015	2	-6	N/A	-5	N/A
12/31/2014	3	-6	N/A	-5	N/A
12/31/2013	2	-9	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VBIV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VBIV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VBIV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VBIVの収益 ( 48.9% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: VBIVの収益 ( 48.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VBIVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

VBI Vaccines 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 291%, EPS downgraded

Consensus EPS estimates upgraded to US$4.46 loss

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

Consensus EPS estimates fall by 1,377%

No longer forecast to breakeven

Recent updates

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Consensus forecasts updated

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?